Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Carbapenem

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    DoP Extends PLI Timeline for Bulk Drugs to Jan. 16, 2026
    DoP Extends PLI Timeline for Bulk Drugs to Jan. 16, 2026

    30 Dec 2025

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=183296&sid=1

    PHARMABIZ
    30 Dec 2025
    Share Share
    GSK Resubmits Tebipenem HBr NDA To FDA For Complicated UTIs
    GSK Resubmits Tebipenem HBr NDA To FDA For Complicated UTIs

    19 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/19/3208446/0/en/Spero-Announces-NDA-Resubmission-of-Tebipenem-HBr-by-GSK-to-the-FDA-for-the-Treatment-of-Complicated-Urinary-Tract-Infections-Including-Pyelonephritis.html

    GLOBENEWSWIRE
    19 Dec 2025
    Share Share
    DoP Seeks Applications For PLI Scheme To Produce 2 Bulk Drugs
    DoP Seeks Applications For PLI Scheme To Produce 2 Bulk Drugs

    01 Dec 2025

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=182742&sid=1

    PHARMABIZ
    01 Dec 2025
    Share Share
    Omnix Medical, Prevail Partners Unveil Strategic Financial
    Omnix Medical, Prevail Partners Unveil Strategic Financial

    06 Nov 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-11-06/omnix-medical-and-prevail-partners-llc-announce-strategic-and-financial-partnership

    PHARMIWEB
    06 Nov 2025
    Share Share
    Ph3 PIVOT-PO Data Show Tebipenem HBr as First Oral Carbapenem
    Ph3 PIVOT-PO Data Show Tebipenem HBr as First Oral Carbapenem

    21 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/21/3169930/0/en/PIVOT-PO-Phase-3-Data-Show-Tebipenem-HBr-s-Potential-as-the-First-Oral-Carbapenem-Antibiotic-for-Patients-with-Complicated-Urinary-Tract-Infections-cUTIs.html

    GLOBENEWSWIRE
    21 Oct 2025
    Share Share
    Spero Pharma Presents Tebipenem Hbr Data At IDweek
    Spero Pharma Presents Tebipenem Hbr Data At IDweek

    14 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/14/3166146/0/en/Spero-Therapeutics-Announces-Presentations-on-Tebipenem-Hbr-at-IDWeek.html

    GLOBENEWSWIRE
    14 Oct 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.